Abstract
AbstractIn the context of molecularly targeted radiotherapy, dosimetry concerns in off-target tissues are a major limitation to the more wide-spread application of radiopharmaceuticals to treat diseases like cancer. Reducing off-target accumulation of radionuclides in background tissues, whilst maintaining high and specific uptake in disease sites and improving the therapeutic window, requires rethinking common radiotracer design concepts. This article explores ways in which innovative radiotracer chemistry (the making and breaking of bonds) is used to modify interactions with the host organism to control excretion profiles and dosimetry at the tissue-specific level.
Funder
HORIZON EUROPE Framework Programme
HORIZON EUROPE European Innovation Council
Publisher
Springer Science and Business Media LLC
Reference131 articles.
1. Sgouros, G., Bodei, L., McDevitt, M. R. & Nedrow, J. R. Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat. Rev. Drug Discov. 19, 589–608 (2020).
2. Strosberg, J. et al. Phase 3 Trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N. Engl. J. Med. 376, 125–135 (2017).
3. Sartor, O. et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N. Engl. J. Med. 385, 1091–1103 (2021).
4. Research, P. Nuclear Medicine Market. https://www.precedenceresearch.com/nuclear-medicine-market/ ‘The global nuclear medicine market, forecast period 2024 to 2033.’ (2024).
5. Holland, J. P., Williamson, M. J. & Lewis, J. S. Unconventional nuclides for radiopharmaceuticals. Mol. Imaging 9, 1–20 (2010).